Most Read Articles
Jairia Dela Cruz, 6 days ago
In patients with heart failure with preserved ejection fraction (HFpEF), angiotensin-neprilysin inhibition with sacubitril/valsartan confers better renoprotection than valsartan alone, reducing the risk of adverse renal events and the speed of decline in estimated glomerular filtration rate (eGFR), a study has found.
5 days ago
Dupilumab solution for injection (pre-filled syringe) 200 mg/1.14 mL and 300 mg/2 mL
Jairia Dela Cruz, 5 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Dr. Tai-Pang Ip, Dr. Sze-Hung Wong, 04 Sep 2020
Osteoporosis (OP) is a disabling condition associated with significant morbidity and mortality. Management of OP requires a multidisciplinary approach, with choice of treatment based on patients’ fracture risk. At a virtual symposium organized by the Osteoporosis Society of Hong Kong (OSHK), Dr Tai-Pang Ip, Specialist in Endocrinology, Diabetes and Metabolism in Hong Kong, and Dr Sze-Hung Wong, Specialist in Orthopaedics and Traumatology in Hong Kong, discussed the diagnosis and management of OP in primary care and the role of antiresorptive and bone-forming agents in treatment of OP in high-risk patients.

Optimizing outcomes when reversing neuromuscular block following surgery: Expert case discussions

15 May 2020
Neuromuscular block (NMB) is an essential part of surgery.However, effective reversal of NMB following surgery is necessaryto assist recovery and avoid serious complications associated withresidual blockade. The cases presented here outline the potentialbenefits of using sugammadex for NMB reversal.


Sponsored as a service to the medical profession by MSD.
MERCK SHARP & DOHME (ASIA) LTD.
27/F, Lee Garden Two, 28 Yun Ping Road, Causeway Bay, Hong Kong.
TEL: (852) 3971 2800
FAX: (852) 2834 0756
Website: www.msd.com.hk
This information is provided as a professional service by Merck Sharp & Dohme (Asia) Ltd. The views expressed in the publication reflect the experience and opinions of the authors. For any product mentioned in this publication, the prescribing information from the company (manufacturer) should be consulted prior prescribing.
HK-XBR-00017 03/20
Copyright © 2020 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved.



Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Hong Kong digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 6 days ago
In patients with heart failure with preserved ejection fraction (HFpEF), angiotensin-neprilysin inhibition with sacubitril/valsartan confers better renoprotection than valsartan alone, reducing the risk of adverse renal events and the speed of decline in estimated glomerular filtration rate (eGFR), a study has found.
5 days ago
Dupilumab solution for injection (pre-filled syringe) 200 mg/1.14 mL and 300 mg/2 mL
Jairia Dela Cruz, 5 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Dr. Tai-Pang Ip, Dr. Sze-Hung Wong, 04 Sep 2020
Osteoporosis (OP) is a disabling condition associated with significant morbidity and mortality. Management of OP requires a multidisciplinary approach, with choice of treatment based on patients’ fracture risk. At a virtual symposium organized by the Osteoporosis Society of Hong Kong (OSHK), Dr Tai-Pang Ip, Specialist in Endocrinology, Diabetes and Metabolism in Hong Kong, and Dr Sze-Hung Wong, Specialist in Orthopaedics and Traumatology in Hong Kong, discussed the diagnosis and management of OP in primary care and the role of antiresorptive and bone-forming agents in treatment of OP in high-risk patients.